Journal: Scientific Reports

Article Title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products

doi: 10.1038/s41598-020-63794-y

Figure Lengend Snippet: Anti-HAV Ig titers of plasma pools segregated by donor center. Plots demonstrate the spread of observed anti-HAV Ig titers measured by ELISA. The box whiskers denote the minimum and maximum titers; the bottom and top borders of a box represent the first and third quartile markers, respectively; the line within each box denotes the median, and the (+) symbol denotes the mean. (*) Mean is significantly greater than those of San Diego-CA, Midwest City-OK, Provo-UT, and Clarksville-TN, centers (p < 0.001; ANOVA, Tukey’s HSD). (#) Mean is significantly greater than those of Provo-UT, and Clarksville-TN, centers (p < 0.0001; ANOVA, Tukey’s HSD).

Article Snippet: A commercially-available enzyme-linked immunosorbent assay (ELISA) (Bio-Rad MONOLISATM Anti-HAV EIA Kit, cat#72496) was used to estimate the anti-HAV Ig (IgG and IgM) titer in a plasma sample.

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products

doi: 10.1038/s41598-020-63794-y

Figure Lengend Snippet: Anti-MeV and anti-CMV IgG titers of plasma pools from select donor centers. Plots demonstrate the spread of anti-MeV and anti-CMV IgG ELISA observations—reported as signal-to-cutoff (S·Co −1 )—in plasma pools from high-titer (El Paso-TX) and mid-titer (Midwest City-OK) donor centers. The box whiskers denote the minimum and maximum titers; the bottom and top borders of a box represent the first and third quartile markers, respectively; the line within each box denotes the median, and the (+) symbol denotes the mean. (*) Mean is greater than that of the El Paso, TX, center (p < 0.0001; unpaired two-tail t test).

Article Snippet: A commercially-available enzyme-linked immunosorbent assay (ELISA) (Bio-Rad MONOLISATM Anti-HAV EIA Kit, cat#72496) was used to estimate the anti-HAV Ig (IgG and IgM) titer in a plasma sample.

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products

doi: 10.1038/s41598-020-63794-y

Figure Lengend Snippet: Spread of anti-HAV Ig titers of individual plasma units composing pools obtained from high-titer, mid-titer, and low-titer donor centers. Plots demonstrate the spread of anti-HAV Ig titers measured by ELISA in plasma pools from high-titer (El Paso-TX and McAllen-TX), mid-titer (Midwest City-OK), and low-titer (Clarksville, TN) donor centers. The box whiskers denote the minimum and maximum titers; the bottom and top borders of a box represent the first and third quartile markers, respectively; the line within each box denotes the median, and the (+) symbol denotes the mean.

Article Snippet: A commercially-available enzyme-linked immunosorbent assay (ELISA) (Bio-Rad MONOLISATM Anti-HAV EIA Kit, cat#72496) was used to estimate the anti-HAV Ig (IgG and IgM) titer in a plasma sample.

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

doi: 10.1016/j.omtm.2025.101646

Figure Lengend Snippet: Progressive reduction of both serum HBeAg and HBsAg upon blocking of cccDNA replenishment (A) Experimental procedures and time course of HBV infection and treatment evaluation using uPA/SCID chimeric mice model. (B1) The expressed anti-HBs antibody levels were >100,000 mIU/mL and sustained at steady levels for 200 days after a single injection of HBVZ10 in 8 chimeric mice (T1 and CT1-CT7) infected with HBV. A pretreatment serum sample from each replicate was used as a negative control, and all pretreatment anti-HBs antibody levels were plotted as 1 mIU/mL for consistency. (B2) Average anti-HBs antibody levels per group. HBVZ10 was administered on day 11 with a dose of 2.5E10 copies for mice CT1-CT4 on day 22 with 1.8E11 copies for mice T1 and CT5-CT6, or on day 44pi with 7E11 copies of HBV10 for mouse CT7. All 7 mice (CT1-CT7) also received 12-week ETV 10 days after HBVZ10 injection. T. HBVZ10 monotherapy. CT: Combination of HBVZ10 with ETV. (C1) Serum HBeAg kinetics among 7 mock-treated mice (MT1-MT7 blue) and 8 treated mice (T1 and CT1-CT7 green). Serum HBeAg levels are expressed as the OD ratio of the tested sample to the mean OD of three negative controls. A ratio greater than 2.1 is considered positive. (C2) Average serum HBeAg levels per group between mock-treated (blue) and treated (green) from B1. (D1) Kinetic serum HBsAg levels (IU/mL) among mock-treated 7 mice (blue) and 8 treated mice (green) from B1. (D2) Average serum HBsAg levels per group between mock-treated (blue) and treated group (green) from C1. (E) Comparison of average cccDNA levels between mock-treated and combination treated groups (cccDNA was undetectable in mice CT2 and CT4 and not plotted). (F) Comparison of average rcDNA levels between mock-treated and combination-treated groups. Statistical significance was determined using Student’s t test; p < 0.05 was considered significant. Error bars: standard deviation (SD).

Article Snippet: Blood was collected triweekly for quantification of serum HBV DNA (qPCR), HBeAg (CSB-E13557h, CUSABIO), HBsAg (GS HBsAg EIA 32591, Bio-Rad), anti-HBs antibody (MONOLISA anti-HBs EIA 25200, Bio-Rad) with calibrators (MONOLISA anti-HBs 20-Calibrator kit 25219, Bio-Rad), and human albumin (human albumin ELISA kit E−80AL, Immunology Consultants Laboratory) levels by ELISA per instructions.

Techniques: Blocking Assay, Infection, Injection, Negative Control, Comparison, Standard Deviation

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

doi: 10.1016/j.omtm.2025.101646

Figure Lengend Snippet: Add-on of HBVZ10/anti-HBs antibodies to 9-week ETV treatment prevented HBV relapse, leading to progressive reduction of both serum HBeAg and HBsAg levels (A) Experimental procedures and time course of HBV infection and treatment evaluation using uPA/SCID chimeric mice model. (B) Serum HBV DNA (copies/mL log10) kinetics in mock-treated (MT1-MT8 blue) and ETV monotherapy (ET1-ET4 orange) group. (C) Serum HBV DNA kinetics in 8 ETV-treated mice (CT1-CT8) with add-on with a single dose of 1E10 copies of HBVZ10 on day 70pi, then anti-HBs levels were further boosted with administration of mouse anti-HBs at a dose of 250 μg/injection triweekly started on day 99 or later. (D) Average serum HBV DNA levels (copies/mL log10) among 3 groups. (E1) Serum kinetic anti-HBs antibody levels (mIU/mL) expressed by HBVZ10 and boosted by infusions of mouse anti-HBs antibody among the 8 mice (CT1-CT8). Dashed line: 100,000 mIU/mL. Note: Anti-HBs antibody levels exhibited significant fluctuations in some mice receiving triweekly infusions of mouse anti-HBs antibody, contrasting the steady and consistent antibody levels expressed by sufficient HBVZ10 doses ( A). A pretreatment serum sample from each replicate was used as a negative control, and all pretreatment anti-HBs antibody levels were plotted as 1 mIU/mL for consistency. (E2) Average anti-HBs antibody levels (mIU/mL) per group. (F1) Kinetic serum HBsAg levels (IU/mL) among 2 mice with mock-treated (MT1 and MT2 blue), 2 mice with 9-week of ETV therapy (ET1 and ET2 yellow), and 8 mice with 9-week of ETV and anti-HBs antibodies add-on (CT1-CT8 green). (F2) Average serum HBsAg levels (IU/mL) per group. (G1) Kinetic serum HBeAg levels among 2 mice with mock-treated (MT1 and MT2 blue), 2 mice with 9-week of ETV therapy (ET1 and ET2 yellow), and 8 mice with 9-week of ETV and anti-HBs antibodies add-on (CT1-CT8 green). Note. Mouse CT5 had relatively higher baseline HBeAg level and HBeAg remained detectable on termination day (day 218 PI) despite progressive reduction. Serum HBeAg levels are expressed as the OD ratio of the tested sample to the mean OD of three negative controls. A ratio greater than 2.1 is considered positive. (G2) Average serum HBeAg levels per group. (H and I) Comparison of intracellular cccDNA and rcDNA levels among 2 livers with 9-week of ETV therapy (ET1 and ET2 yellow), 2 livers with mock-treated (MT1 and MT2 blue), and 6 livers with 9-week of ETV and anti-HBs antibodies add-on, 5 (CT1-CT3, CT7 and CT8) of them achieved progressive reduction of both serum HBeAg and HBsAg to undetectable levels and the remaining one with detectable serum HBeAg on the termination day (CT5). The differences in cccDNA and rcDNA levels were analyzed by Student t test, p < 0.05 considered significant. Error bars: standard deviations (SD). The limit of detection for HBV DNA is 100 copies/mL and 0.05 IU/mL for serum HBsAg.MT: mock-treated. ET: ETV Monotherapy. CT: 9-week of ETV and anti-HBs antibodies add-on.

Article Snippet: Blood was collected triweekly for quantification of serum HBV DNA (qPCR), HBeAg (CSB-E13557h, CUSABIO), HBsAg (GS HBsAg EIA 32591, Bio-Rad), anti-HBs antibody (MONOLISA anti-HBs EIA 25200, Bio-Rad) with calibrators (MONOLISA anti-HBs 20-Calibrator kit 25219, Bio-Rad), and human albumin (human albumin ELISA kit E−80AL, Immunology Consultants Laboratory) levels by ELISA per instructions.

Techniques: Infection, Injection, Negative Control, Comparison